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OBJECTIVES This study tested the effect of oral prednisone on clinical and angiographic restenosis rate after
successful stent implantation in patients with persistent elevation of systemic markers of
inflammation after the procedure.
BACKGROUND Experimental studies have shown that corticosteroids have the potential to reduce the
inflammatory response associated with stent implantation.
METHODS Eighty-three patients undergoing successful stenting with C-reactive protein (CRP) levels
0.5 mg/dl 72 h after the procedure were randomized to receive oral prednisone or placebo
for 45 days. The primary clinical end point was 12-month event-free survival rate (defined as
freedom from death, from myocardial infarction, and from recurrence of symptoms requiring
additional revascularization). The angiographic end points were restenosis rate and late loss
at six months.
RESULTS Twelve-month event-free survival rates were 93% and 65% in patients treated with
prednisone and placebo, respectively (relative risk [RR] 0.18, 95% confidence intervals [CI],
0.05 to 0.61, p  0.0063). Six-month restenosis rate and late loss were lower in
prednisone-treated than in placebo-treated patients (7% vs. 33%, p  0.001, and 0.39  0.6
mm vs. 0.85  0.6 mm, p  0.001, respectively).
CONCLUSIONS In patients with persistently high CRP levels after successful coronary artery stent implan-
tation, oral immunosuppressive therapy with prednisone results in a striking reduction of
clinical events and angiographic restenosis rate. (J Am Coll Cardiol 2002;40:1935–42)
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Successful treatment of patients with stenotic coronary
arteries by percutaneous transluminal coronary angioplasty
(PTCA) with stent implantation is associated with resteno-
sis in approximately 10% to 50% of cases (1–4). Restenosis
after stent implantation is mainly caused by neointimal
proliferation through the stent struts (5–7). Experimental
studies indicate a marked activation of inflammatory cells at
the site of stent struts, which is likely to play a key role in the
process of neointimal proliferation and restenosis (8–12).
Indeed, interleukin-1 and -6, secreted by activated macro-
phages, are powerful stimuli for smooth muscle cell prolif-
eration. Of note, interleukin-1 and -6 are also hepatocyte-
stimulating factors inducing the production of acute-phase
proteins including C-reactive protein (CRP) (13–16). Ac-
cordingly, preprocedural high plasma levels of CRP and a
persistent elevation of plasma levels of CRP following
successful stent implantation have been found to predict the
risk of restenosis (17,18).
Although the powerful anti-inflammatory effects of cor-
ticosteroids are well known (19), previous studies in humans
failed to demonstrate a significant reduction of restenosis
rate after successful PTCA in unselected populations of
anginal patients (20–22). However, the data presently
available regarding the use of corticosteroids in patients
undergoing coronary artery stent implantation are meager.
We carried out a double-blind, randomized, placebo-
controlled study to assess the effects of oral prednisone on
restenosis rate after successful stent implantation in patients
with persistently high plasma levels of CRP after the
procedure and, therefore, more likely to be susceptible to the
anti-inflammatory effects of treatment.
METHODS
Patient selection. The study population consisted of pa-
tients enrolled from two centers with the following charac-
teristics: typical angina pectoris, documented myocardial
ischemia, or both; one-vessel or multiple-vessel disease
(defined as a reduction 50% of the luminal diameter, as
measured by quantitative computerized angiography) un-
dergoing successful implantation of a single stent of a length
19 mm; CRP0.5 mg/dl before stenting and0.5 mg/dl
72 h after the procedure. The reason only one lesion was
treated in patients with multivessel disease was because the
other lesions were localized in a totally occluded vessel, in
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vessels not susceptible to be treated percutaneously or
surgically, or in vessels supplying infarcted myocardial
regions with no evidence of residual ischemia. Exclusion
criteria were unstable angina (Braunwald class III); previous
myocardial infarction (MI) in the last six weeks; treatment
of restenotic lesions or vein graft stenosis; total occlusions;
connective tissue diseases; renal failure; left ventricular
ejection fraction 40%; New York Heart Association func-
tional class II; steroid therapy within the preceding 30
days; contraindication to steroid use including active infec-
tive diseases, active peptic ulcer, diabetes treated with
medical therapy, uncontrolled severe hypertension, preg-
nancy. The study protocol was approved by the Institutional
Ethics Committee in each center, and written informed
consent was obtained for all patients.
Study design. After eligibility, patients were randomly
assigned to either placebo or prednisone group. In a double-
blind fashion, either prednisone (Deltacortene, Bruno
Farmaceutici, Rome, Italy) or placebo was given orally 72 h
after the procedure according to the following protocol: 1
mg/kg for the first 10 days; 0.5 mg/kg from day 11 to day
30; 0.25 mg/kg from day 31 to day 45. The dosage of
prednisone was chosen according to the standardized im-
munosuppressive protocol utilized for heart transplantation
(23).
Clinical evaluation. Exertional angina was classified ac-
cording to the system of the Canadian Cardiovascular
Society (CCS) (24). Patients were classified as having
unstable angina according to Braunwald’s criteria (25).
Patients were classified as having had an MI according to
World Health Organization (WHO) criteria (26). Conven-
tional risk factors were examined by direct questioning of
patients and by a review of hospital records, as previously
described (27).
Stent implantation. Three days before the procedure all
patients were treated with aspirin 325 mg once daily and
ticlopidine 250 mg twice daily. A bolus of 100 U/kg of
heparin was administered after sheath insertion, and sup-
plemental doses were then given to maintain an activated
clotting time 300 s. The stent type, the need for predila-
tion, and the final size of the balloon for stent implantation
were chosen by the operator to obtain a close to zero
angiographic residual stenosis. Only balloon-expandable,
stainless steel tubular stents with multicellular design were
used. After the procedure, arterial sheath was removed when
the activated clotting time was 150 s.
Patients continued to receive aspirin 325 mg once daily
indefinitely, ticlopidine 250 mg twice daily for four weeks,
and pantoprazole 40 mg once daily for 45 days.
Laboratory assessment. Venous blood samples were ob-
tained on admission to the hospital and 72 h after the
procedure. Plasma samples for CRP concentration were
analyzed by an immunoturbidimetric method (Roche Uni-
mate 3 CP, Milan, Italy). The normal upper reference value
for CRP with this method is 0.5 mg/dl. For total creatine
kinase (CK), the MB isoform of creatine kinase (CK-MB),
and for cardiac troponin I, venous blood samples were
obtained immediately before the procedure and 6, 24, and
48 h after the procedure. Plasma samples were analyzed for
CK and CK-MB with commercially available immuno-
chemical tests and cardiac troponin I by an immunoenzy-
matic “sandwich” assay. Non–Q-wave MI was defined as
post-procedural CK-MB elevations 3 times the upper
normal limit.
Clinical and angiographic assessment. Patients were seen
in outpatient clinic at 1, 3, 6, and 12 months. Follow-up
coronary angiography was performed six months after the
initial procedure or earlier if symptoms suggestive of coro-
nary restenosis developed before that time. The angio-
graphic end points were restenosis rate (defined as an
in-stent stenosis 50% at follow-up coronary angiography)
and late loss (defined as the minimal luminal diameter
[MLD] after the procedure minus the value at six-month
follow-up).
The clinical end point was 12-month event-free survival
rate, defined as freedom from death, from MI, or from
recurrence of symptoms requiring additional revasculariza-
tion.
Angiography was performed in two orthogonal views
after intracoronary administration of 200 g of nitroglyc-
erin. Angiographic variables were assessed before the pro-
cedure, immediately after, and at follow-up; the same two
orthogonal views were always obtained. All angiograms
were analyzed in an independent centralized core laboratory
(European Imaging Laboratory, Rome, Italy). Quantitative
angiography analysis was done by use of the automated
edge-detection system CMS (Medis Medical Imaging Sys-
tems) (28) by experienced technicians who were unaware of
the study protocol. Both high accuracy and precision for this
system have been previously demonstrated (28). Nonethe-
less, 40 randomly selected measurements were reanalyzed by
a blinded observer. Results were reproducible. The mean of
the difference between measurements was 0.05  0.2 mm
(p  0.45) for MLD and 0.09  0.35 mm (p  0.40) for
diameter stenosis.
An independent Data and Safety Monitoring Board was
instructed to verify the incidence of clinical events and to
review patient records.
Statistical analysis. Patients were randomized according to
a computer-generated random code. We calculated the size
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of the sample necessary to achieve 80% statistical power at
a two-sided significance level of 0.05. The calculated sample
size was based on a previous report of about 24% of clinical
restenosis at 12 months in stable patients with levels of CRP
0.5 mg/dl 72 h after stent implantation (17). Because
clinical restenosis rate underestimates at about 10% the
incidence of in-stent restenosis, we assumed that the reste-
nosis rate in this subset of high-risk patients was 35%. To
justify a pharmacotherapeutic intervention with a high dose
of prednisone, we required a reduction of restenosis rate to
5%. Assuming a 20% drop-out rate, we set a goal of 83
patients for the study. The end points of the study were the
event-free survival at 12 months and the occurrence of
in-stent restenosis at 6 months. All end-point analyses were
performed on an intention-to-treat basis, with all random-
ized patients included in the analyses.
Continuous variables are expressed as mean  SD and
compared by unpaired Student t test; nominal variables are
expressed as proportions and compared by chi-squared test
or the Fisher exact test as appropriate. Event-free survival
curves were obtained by the Kaplan-Meier method and
compared by log-rank test. The association of drug therapy
with the end point of the study was assessed by Cox
proportional hazard regression analysis. Univariate analysis
was also applied to assess the association of other clinical
and angiographic variables with the end point of the study.
Stepwise multivariate Cox regression analysis was used to
assess the independent association of drug therapy with the
end point, by adjusting for other significant variables. To
this aim, all variables with a p value 0.1 at univariate
analysis were considered in the regression model. Variables
were inserted in the model in decreasing order, according to
univariate statistical significance.
For purposes of Cox analysis some continuous variables
were dichotomized as follows: 1) anginal classification at
presentation: stable vs. unstable angina; 2) Thrombolysis In
Myocardial Infarction (TIMI) flow grade before and after
the procedure (TIMI flow grade 3 vs. TIMI flow grade3).
A two-tailed p value 0.05 was always requested for
statistical significance. All statistical analyses were per-
formed with Statview (version 5.0) for Windows 8.0 (SAS
Institute).
RESULTS
Clinical and angiographic characteristics of the patients.
Between January 1999 and March 2001, a total of 527
consecutive patients with normal basal levels of CRP
underwent successful stent implantation in the participating
centers, of whom 137 had CRP levels persistently higher
than 0.5 mg/dl 72 h after the procedure. Of these, 50
patients did not meet the inclusion criteria, 4 did not give
consent, and 83 (71 men; mean age 64  9 years; range, 40
to 80 years) were enrolled in the study. Forty-one patients
were randomly assigned to receive prednisone and 42 to
receive placebo. No significant differences existed in clinical
or angiographic characteristics between the two groups
(Tables 1 and 2).
Drop-out and collateral effects. Two patients assigned to
placebo treatment dropped out of the study after random-
ization because they withdrew their consent to repeat
angiography at six months. Systemic therapy with pred-
Table 1. Baseline Clinical Characteristics of the 83 Patients
Characteristic
Prednisone Group
(n  41)
Placebo Group
(n  42) p Value
Age (yrs) 63  9 65  9 0.15
Male gender, n (%)* 32 (83) 37 (88) 0.23
Risk factors, n (%)
Current smoker 12 (29) 11 (26) 0.38
Diabetes mellitus 0 (0) 0 (0)
Hypercholesterolemia† 18 (44) 18 (43) 0.46
Hypertension 16 (39) 15 (35) 0.38
Family history 13 (32) 10 (24) 0.21
Obesity*‡ 2 (5) 3 (7) 0.78
Exertional angina (CCS class), n (%)*§
I 6 (15) 10 (24)
II 14 (34) 11 (26) 0.17
III 14 (34) 13 (30)
IV 2 (5) 4 (10)
Unstable angina (Braunwald class III)* 5 (12) 4 (10) 0.9
Medical treatment, n (%)
Aspirin 34 (83) 36 (86) 0.37
Beta-blockers 16 (39) 15 (36) 0.38
Calcium antagonists 18 (44) 17 (40) 0.38
Nitrates 16 (39) 20 (48) 0.22
Statins* 6 (15) 4 (10) 0.51
ACE inhibitors 14 (34) 13 (31) 0.38
Plus-minus values are means  SD. *Fisher exact test was used. †Total cholesterol 200 mg/dl. ‡Body mass index 27.8 in
men and 27.3 in women. §According to the classification system of the Canadian Cardiovascular Society (CCS).
ACE  angiotensin-converting enzyme.
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nisone was well tolerated: one patient randomized to pred-
nisone complained of severe gastric pain five days after
randomization and stopped the therapy. Two patients with
moderate hypertension controlled by drug treatment before
stent implantation needed upgrading of antihypertensive
treatment during the study period. One patient exhibited
transient glucose intolerance, which normalized after the
study period. One patient randomized to placebo com-
plained of gastric pain.
In-hospital clinical outcome. In-hospital outcome was
similar between the two groups (Table 3). No patient had
subacute thrombosis and/or non–Q-wave MI after stent
implantation procedure. Post-procedural CK, CK-MB, and
troponin I levels were always within normal range (Table 4).
Clinical outcome at 12 months. Planned clinical
follow-up data were available for all randomized patients.
Clinical events at 12 months are detailed in Table 3. A
primary clinical end point was reached by 3 of the 41
patients randomly assigned to prednisone group (7%), as
compared with 15 of the 42 patients randomly assigned to
placebo group (35%). All these patients had documented
restenosis of the target vessel, which resulted in an acute MI
Table 2. Baseline Angiographic and Procedural Characteristics
Characteristic
Prednisone Group
(n  41)
Placebo Group
(n  42) p Value
Ejection fraction (%) 57  10 56  7 0.84
Artery affected, n (%)
Left anterior descending coronary 22 (53) 21 (50)
Right coronary 8 (20) 11 (26) 0.76
Circumflex coronary 11 (27) 10 (24)
Type of lesion, (%)*†
A 10 10
B1 51 57
B2 29 26 0.7
C 10 7
Reference diameter (mm) 3.06  0.47 3.13  0.62 0.61
Percent stenosis (%) 71  9 70  11 0.53
Maximal inflation pressure (atm) 11  2.0 11  3.0 0.66
Total duration of inflation (s) 44  18 46  15 0.69
Balloon diameter (mm) 3.43  0.38 3.43  0.45 0.98
Final stenosis (%) 14  9 15  9 0.91
Minimal luminal diameter (mm) 2.75  0.4 2.73  0.5 0.81
Vessel disease, n (%)*
One vessel 23 (56) 25 (59)
Two vessels 14 (34) 12 (29) 0.84
Three vessels 4 (10) 5 (12)
Plus-minus values are means  SD. *Fisher exact test was used. †Lesions classified according to the system of the American
College of Cardiology–American Heart Association Task Force.
Table 3. Clinical Outcome in the Hospital and During
Follow-Up
Event
Prednisone
Group
(n  41)
Placebo
Group
(n  42) p Value
In hospital, n (%)
Procedural success 41 (100) 42 (100)
Procedural failure 0 0
Vascular complications 0 0
Non–Q-wave MI 0 0
Subacute thrombosis 0 0
At 12 months, n (%)
Event-free survival 38 (93) 27 (65) 0.0063
Death 0 (0) 1 (2) 0.16
Nonfatal infarction 0 (0) 1 (2) 0.16
Additional revascularization* 3 (7) 14 (33) 0.001
Any event 3 (7) 15 (35) 0.0063
*All additional interventions were target vessel revascularizations.
MI  myocardial infarction.
Table 4. Levels of CK, CK-MB, and Troponin I Before and 6,
24, 48 h After the Procedure; Levels of CRP Before and 72 h
After the Procedure
Prednisone
Group
(n  41)
Placebo
Group
(n  42) p Value
Basal
CK (U/l) 75  34 70  32 0.24
CK-MB (U/l) 8  7 9  5 0.40
Troponin I, ng/ml 0.05  0.03 0.05  0.02 0.42
CRP, mg/l 3.0  0.6 3.0  0.8 0.95
6 h after the procedure
CK (U/l) 80  37 76  39 0.55
CK-MB (U/l) 9  6 8  7 0.49
Troponin I, ng/ml 0.07  0.03 0.05  0.04 0.63
24 h after the procedure
CK (U/l) 82  44 81  36 0.70
CK-MB (U/l) 12  6 13  7 0.59
Troponin I, ng/ml 0.08  0.04 0.07  0.06 0.59
48 h after the procedure
CK (U/l) 90  43 87  46 0.61
CK-MB (U/l) 13  5 14  9 0.41
Troponin I, ng/ml 0.04  0.03 0.06  0.04 0.39
72 h after the procedure
CRP, mg/l 18.4  11 17.2  11.7 0.21
CK  creatine kinase; CRP  C-reactive protein.
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in one patient in the placebo arm. One patient died in the
placebo arm.
Log-rank test showed a highly significant statistical
difference between event-free survival curves of the two
study groups (p  0.0016, Fig. 1). Compared with placebo,
the relative risk (RR) reduction of events with prednisone
was 0.18 (95% confidence intervals [CI]: 0.05 to 0.61, p 
0.0063). Stepwise multivariate Cox regression analysis
showed that prednisone therapy was independently associ-
ated with the occurrence of events, when adjusted for
possible confounding variables (RR: 0.15; 95% CI: 0.04 to
0.59; p  0.007). Other covariates, which resulted in being
predictors of the primary end point at univariate analysis,
included presentation with stable angina (RR: 0.26; 95%
CI: 0.08 to 0.80, p  0.018); TIMI flow grade 3 after
coronary stenting (RR: 0.23, 95% CI: 0.07 to 0.80, p 
0.02); and beta-blocking therapy (RR: 0.17, 95% CI: 0.04 to
0.76, p  0.02).
Angiographic outcome at six months. Angiographic
follow-up data were obtained for 98% of the eligible
patients (Table 5). Restenosis at six-month follow-up oc-
curred in 17 patients (20.5%). Of note, three patients (21%)
in the placebo group and one patient (33%) in the treatment
group who had angiographic restenosis at six months were
completely asymptomatic. Restenosis rates were 7% and
33% in the treatment group and control group (p  0.001),
respectively. Late loss and MLD at follow-up were strik-
ingly less in the treatment group than in the control group
(0.39  0.6 vs. 0.85  0.6, p  0.001, and 2.36  0.7 vs.
1.88  0.7 mm, p  0.003, respectively). Frequency
distribution curves for postprocedure and follow-up percent
diameter stenosis of both populations are shown in Figure 2.
DISCUSSION
In this trial, immunosuppressive therapy with prednisone
for 45 days in patients with persistently high CRP levels
after coronary stent implantation was associated with a
striking reduction of 12-month clinical events and 6-month
restenosis rate. Indeed, immunosuppressive therapy resulted
in a 28% absolute reduction of clinical events and in 26%
absolute reduction of restenosis rate.
The key role played by inflammation in neointimal
Figure 1. Event-free survival (death, myocardial infarction, recurrence of symptoms requiring additional revascularization) curves of the two study groups
at 12-month follow-up. The rate of event-free survival was significantly higher in the prednisone group than in the placebo group (p  0.0016 by Cox
proportional hazards regression analysis).
Table 5. Angiographic Outcome at 6 Months
Prednisone
Group
(n  41)
Placebo
Group
(n  42) p Value
Reference diameter (mm) 3.18  0.5 3.15  0.5 0.79
Restenosis, n (%) 3 (7) 14 (33) 0.001
Degree of stenosis (%)* 26  19 41  18 0.0008
Minimal luminal diameter (mm)* 2.36  0.7 1.88  0.7 0.003
Late loss (mm)* 0.39  0.6 0.85  0.6 0.001
Net gain (mm)* 1.48  0.7 0.92  0.7 0.001
Plus-minus values are means  SD. Late loss was calculated as the minimal luminal
diameter after the procedure minus the value at follow-up, and net gain as the
minimal luminal diameter at follow-up minus the value before the procedure. *Refers
to 81 patients who completed angiographic follow-up.
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proliferation after stent implantation has well been docu-
mented in several experimental studies (12) and in a
postmortem study in humans (29), and has recently been
confirmed in several clinical studies showing that elevated
systemic levels of inflammatory markers before or after
percutaneous coronary interventions are associated with a
higher risk of restenosis (17,18,30,31). In particular, find-
ings indicate that a high level of CRP 72 h after successful
coronary stenting is predictive of a worse prognosis at 12
months (17). The high systemic inflammatory response may
be due to a further activation of the inflammatory process
within the plaque itself as well as to injury during coronary
stenting.
Corticosteroids exert a profound inhibitory effect on the
inflammatory processes and influence platelet function,
smooth muscle cell proliferation, and collagen synthesis
(19). Continuous infusion of hydrocortisone over a two-
week period in rabbits subjected to aortic balloon injury was
found to markedly reduce neointimal hyperplasia (12), yet
in previous clinical studies systemic corticosteroid adminis-
tration failed to reduce restenosis after balloon angioplasty.
Stone et al. (20) randomized 102 patients with restenosis
after a first PTCA to receive an intramuscular injection of
125 mg of methylprednisolone immediately before and after
repeat PTCA, followed by 60 mg of oral prednisone for one
week, or placebo. Angiographic follow-up was limited to
53% of patients, and restenosis rate was slightly lower in
corticosteroid-treated patients than in placebo-treated pa-
tients (36% vs. 40%), although this difference did not reach
statistical significance. The randomized, placebo-controlled
M-Heart study (21) confirmed in a larger population that a
single fixed dose of methylprednisolone before PTCA does
not reduce restenosis rate. More recently, in a randomized,
placebo-controlled study, Lee et al. (22) found that a single
fixed dose of methylprednisolone prior to stent implantation
failed to reduce clinical and angiographic restenosis rate.
In this study, treatment with oral prednisone for 45 days
after successful stent implantation in selected high-risk
patients with persistent systemic signs of inflammation after
the procedure was associated with a striking reduction of
clinical and angiographic restenosis rate. Several possible
explanations may account for the different results between
this and previous trials. First, in previous studies steroids
were utilized for short periods often after the procedure.
Conversely, in our study, prednisone was administered for
45 days, with the highest dosage during the first 10 days
(20–22). Indeed, complete neointimal coating of stents is
unlikely to be completed earlier than 28 days after the
procedure, and in this time period exposure of the metal
strut of the stent may trigger a persistent inflammatory
Figure 2. Cumulative frequency distribution curves showing the percentage of stenosis measured at six-month angiographic follow-up. The vertical broken
line indicates the percentage of patients with (right of the line, 33% vs. 7% in placebo [dashed line] and prednisone [solid line] groups, respectively) and
without restenosis (left of the line, 67% vs. 93% in placebo and prednisone groups, respectively).
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response to a “foreign body” in susceptible patients. Second,
in some studies steroids were utilized after balloon angio-
plasty (20,21) rather than after stenting. It is unlikely that
steroids might be helpful in the prevention of recoil and
remodeling, which are the main mechanisms of restenosis
after balloon angioplasty. Finally, previous studies utilized
steroids in unselected populations of patients (20–22) rather
than selectively in high-risk patients with evidence of
enhanced inflammatory response.
Study limitations. The present study has some limitations.
The number of patients enrolled is rather small, although
the sample size, determined on the basis of an expected 80%
reduction of restenosis rate in the treatment group, had a
sufficient power (80% at an alpha level of 0.05) to detect a
significant difference between groups. Nonetheless, because
of the relatively small sample size, it cannot be ruled out that
our results might be false positive, possibly due to chance or
differences in unmeasured variables. Thus, a larger random-
ized trial with prednisone is warranted.
Another limitation is that our study population represents
15% of coronary patients referred to our centers for percu-
taneous coronary interventions. Indeed, for the purpose of
this study, high-risk patients only were enrolled with
persistent elevation of CRP after coronary artery stent
implantation and without clinical contraindication to pred-
nisone therapy. Of note, patients with diabetes, which
represents a major cause of stent restenosis, were excluded
because of the harmful effect of steroid therapy in this subset
of high-risk patients. However, by studying highly selected
patients we could exclude confounding factors due to
heterogeneity of patients with coronary artery disease.
C-reactive protein values were assessed by an immuno-
turbidimetric method and not with the recently recom-
mended high-sensitive CRP assay. However, a recent report
comparing the two assays revealed a close correlation and
indicated that CRP levels 0.5 mg/dl can be reliably
detected using the less expensive immunoturbidimetric
method (18).
Six-month angiographic follow-up might have caused an
underestimation of restenosis, which, in turn, could have
been simply delayed by prednisone. However, this seems
unlikely as 12-month event-free survival rate confirmed the
angiographic results obtained at 6 months. A practical
drawback of this study is the need to measure CRP levels
72 h following the procedure to decide whether to initiate
steroid therapy or not. However, it should be noted that
CRP measurement does not require hospitalization, and
blood sampling may be performed in the outpatient clinic.
Finally, our findings should be evaluated in the context of
the newly developed medicated stents, which have been
shown to be very effective in the prevention of in-stent
restenosis (32). If initial positive results obtained with
medicated stents will be confirmed, systemic therapy with
prednisone might, however, serve as an adjunctive therapy
in selected high-risk patients with persistent evidence of
systemic inflammation after coronary stent implantation, or
even a convenient alternative to expensive drug-eluting
stents. In this context, comparative studies are needed to
define the subgroup of patients who will most benefit from
either therapy.
Conclusions. Our study shows that in patients with per-
sistent systemic inflammatory response after coronary artery
stent implantation, oral therapy with prednisone results in a
striking reduction of 6-month restenosis and 12-month
clinical events. Therapy with prednisone is generally well
tolerated, although it should be carefully monitored to
prevent mild side effects. If our results are confirmed in
larger trials, prednisone therapy may represent a novel,
powerful, and inexpensive treatment for the prevention of
in-stent restenosis in selected patients.
Acknowledgments
The investigators acknowledge the expert secretarial help of
Nadia Crea; Dr. Giovanni Martini, Sigma-Tau technician,
for the excellent technical assistance; and Dr. Gaetano A.
Lanza for his support with the statistical analysis.
Reprint requests and correspondence: Dr. Francesco Versaci,
Divisione di Cardiochirurgia, Universita` di Roma Tor Vergata,
European Hospital, via Portuense 700, 00149 Rome, Italy. E-mail:
francescoversaci@yahoo.it.
REFERENCES
1. Lowe HC, Oesterle SN, Khachigian LV. Coronary in-stent restenosis:
current status and strategies. J Am Coll Cardiol 2002;39:183–93.
2. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of
balloon-expandable-stent implantation with balloon angioplasty in
patients with coronary artery disease. BENESTENT Study Group.
N Engl J Med 1994;331:489–95.
3. Fischman DL, Leon M, Baim DS, et al. A randomised comparison of
coronary-stent implantation and balloon angioplasty in the treatment
of coronary artery disease. Stent Restenosis Group Investigators.
N Engl J Med 1994;331:496–501.
4. Versaci F, Gaspardone A, Tomai F, et al. A comparison of coronary-
artery stenting with angioplasty for isolated stenosis of the proximal
left anterior descending coronary artery. N Engl J Med 1997;336:817–
22.
5. Dussailant GR, Mintz GS, Pichard AD, et al. Small stent size and
intimal hyperplasia contribute to restenosis: a volumetric intravascular
ultrasound study. J Am Coll Cardiol 1995;26:720–4.
6. Hoffman R, Mintz GS, Dussailant GR, et al. Patterns and mecha-
nisms of in-stent restenosis. A serial intravascular ultrasound study.
Circulation 1996;94:1247–54.
7. Mudra H, Regar E, Klauss V, et al. Serial follow-up after optimized
ultrasound-guided deployment of Palmaz-Schatz stents. In-stent neo-
intimal proliferation without significant reference segment response.
Circulation 1997;95:363–70.
8. Shirotani M, Yui Y, Kawai C. Restenosis after coronary angioplasty:
pathogenesis of neointimal thickening initiated by endothelial loss.
Endothelium 1993;1:5–22.
9. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for
restenosis based on cell biology: clues for the development of new
preventive therapies. J Am Coll Cardiol 1991;17:758–69.
10. Pietersma A, Kofflard M, de Wit EA, et al. Late lumen loss after
coronary angioplasty is associated with the activation status of circu-
lating phagocytes before treatment. Circulation 1995;91:1320–5.
11. De Servi S, Mazzone A, Ricevuti G, et al. Granulocyte activation after
coronary angioplasty in humans. Circulation 1990;82:140–6.
12. Kornowoski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB.
In-stent restenosis: contributions of inflammatory responses and arte-
1941JACC Vol. 40, No. 11, 2002 Versaci et al.
December 4, 2002:1935–42 Corticosteroids and Coronary Restenosis
rial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224–
30.
13. Helle M, Boeije L, Pascaual-Salcedo D, Aarden L. Differential
induction of interleukin-6 production by monocytes, endothelial cells
and smooth muscle cells. Progr Clin Biol Res 1991;367:61–71.
14. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in
coronary artery disease. J Am Coll Cardiol 1994;24:1591–601.
15. Ikeda U, Ikeda M, Oohara T, et al. Interleukin-6 stimulates growth of
vascular smooth muscle cells in a PDGF-dependent manner. Am J
Physiol 1991;250:1713–7.
16. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H.
Interferon-2/B-cell stimulatory factor type 2 shares identity with
monocyte-derived hepatocyte stimulating factor and regulates the
major acute phase protein response in liver cells. Proc Natl Acad Sci
U S A 1987;84:7251–5.
17. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive
protein after successful coronary artery stenting in patients with stable
angina. Am J Cardiol 1998;82:515–8.
18. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Scha¨ch-
inger V, Zeiher AM. Preprocedural C-reactive protein levels and
cardiovascular events after coronary stent implantation. J Am Coll
Cardiol 2001;37:839–46.
19. MacDonald RG, Panush RS, Pepine CJ. Rationale for use of glu-
cocorticoids in modification of restenosis after percutaneous translu-
minal coronary angioplasty. Am J Cardiol 1987;60:56B–60B.
20. Stone GW, Rutherford BD, McConahay DR, et al. A randomized
trial of corticosteroids for the prevention of restenosis in 102 patients
undergoing repeat coronary angioplasty. Cathet Cardiovasc Diagn
1989;18:227–31.
21. Pepine CJ, Hirshfeld JW, MacDonald RG, et al. A controlled trial of
corticosteroids to prevent restenosis after coronary angioplasty. Circu-
lation 1990;81:1753–61.
22. Lee CW, Chae J, Lim H, et al. Prospective randomized trial of
corticosteroids for the prevention of restenosis after intracoronary stent
implantation. Am Heart J 1999;138:60–3.
23. Parbroth MG, Reitz BA. Heart and heart-lung transplantation.
In Braunwald E, editor. Heart Disease. A Textbook of Cardiovas-
cular Medicine. 5th ed. Philadelphia, PA: W.B. Saunders, 1997:
512–33.
24. Campeau L. Grading of angina pectoris. Circulation 1976;54:522–3.
25. Hamm C, Braunwald E. A classification of unstable angina revisited.
Circulation 2000;102:118–22.
26. World Health Organization Principal Investigators (prepared by
Tunstall-Pedoe H). The World Health Organization MONICA
project (MONItoring trends and determinants in CArdiovascular
disease): a major international collaboration. J Clin Epidemiol 1988;
41:105–14.
27. Crea F, Gaspardone A, Tomai F, et al. Risk factors in schoolchildren
associated with a family history of unheralded myocardial infarction or
uncomplicated stable angina in male relatives. J Am Coll Cardiol
1994;23:1472–8.
28. Reiber JHC, van Land CD, Koning G, et al. Comparison of accuracy
and precision of qualitative coronary arterial analysis between cinefilm
and digital system. In: Reiber JHC, Serruys PW, editors. Progress in
Quantitative Coronary Arteriography. Dordrecht, The Netherlands:
Kluwer Academic Publishers, 1994:67–85.
29. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Mueller KM. Acute
and chronic tissue response to coronary stent implantation: pathologic
findings in human specimen. J Am Coll Cardiol 2000;35:157–63.
30. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of
C-reactive protein predict early complications and late restenosis after
coronary angioplasty. J Am Coll Cardiol 1999;34:1512–21.
31. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of
C-reactive protein in patients with unstable angina pectoris under-
going coronary artery stent implantation. Am J Cardiol 2000;85:
92–5.
32. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison
of a sirolimus-eluting stent with a standard stent for coronary revas-
cularization. N Engl J Med 2002;346:1773–80.
1942 Versaci et al. JACC Vol. 40, No. 11, 2002
Corticosteroids and Coronary Restenosis December 4, 2002:1935–42
